The regulation of cannabis-based medicinal products across jurisdictions
Cannabis-based medicinal products are often referred to as “cannabis-based products for medicinal use in humans” and will, for the purposes of this article, be referred to as CBPMs hereafter. CBPMs are today authorized to be administered as a medicine in many countries, including Luxembourg. In view...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Article ou chapitre numérique |
| Jazyk: | Français |
| Vydáno: |
2020
|
| On-line přístup: | Accès Université d'Orléans et IFPM Accès Université d'Orléans et IFPM |
| Shrnutí: | Cannabis-based medicinal products are often referred to as “cannabis-based products for medicinal use in humans” and will, for the purposes of this article, be referred to as CBPMs hereafter. CBPMs are today authorized to be administered as a medicine in many countries, including Luxembourg. In view of the above, we consider the current state of the legislation and distribution of CBPMs across multiple jurisdictions around the world, such as Australia, Austria, Canada, Denmark, Germany, Italy, Luxembourg, the Netherlands, Poland, Spain and the United Kingdom. The law referred to in this article is accurate as at 28 January 2020. The legal framework relating to the regulation of CBPMs is under regular review in a number of jurisdictions and therefore subject to change. The contents of this article do not contain, nor consist in, any legal advice. |
|---|